Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Boehringer Spiriva For COPD Maintenance Therapy Approved By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Anticipating strong demand for the inhalation therapy, Pfizer and Boehringer are delaying launch until mid-year to ensure sufficient initial supplies of tiotropium bromide.

You may also be interested in...



Pfizer/Boehringer Ingelheim’s Spiriva Linked To Stroke In FDA MedWatch Alert

Pooled analyses of data on COPD treatment show increased risk of stroke in two patients per 1,000, agency says.

Pfizer/Boehringer Ingelheim’s Spiriva Linked To Stroke In FDA MedWatch Alert

Pooled analyses of data on COPD treatment show increased risk of stroke in two patients per 1,000, agency says.

Pfizer/Boehringer Spiriva Launched At 30% Discount To Advair For COPD

The average wholesale price for a 30-day supply of tiotropium is $115.20, versus $163.41 for fluticasone/salmeterol. Spiriva is now available nationwide, four months after approval.

Topics

UsernamePublicRestriction

Register

PS058659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel